1035875-01-4

RETRA is an anticancer agent. It acts by exerting anticancer activity in Ewing's sarcoma cells independent of their TP53 status.

RETRA (hydrobromide) is a mutant p53-dependent activator of p73 that can inhibit cancer cells carrying mutant p53. RETRA (hydrobromide) increases the expression level of p73, induces transcriptional activation of several common to transcriptional targets p53 and p73, which leads to mutant p53- and p73-dependent inhibition of tumor growth, reduction of colony formation and induction of effector caspases[1].

[1] Kravchenko JE, et al. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6302-7. DOI:10.1073/pnas.0802091105